Compare MI & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MI | HAE |
|---|---|---|
| Founded | 2009 | 1971 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.3M | 3.9B |
| IPO Year | N/A | 1991 |
| Metric | MI | HAE |
|---|---|---|
| Price | $5.45 | $57.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $86.00 |
| AVG Volume (30 Days) | 10.7K | ★ 1.1M |
| Earning Date | 05-07-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.84 |
| EPS | N/A | ★ 3.65 |
| Revenue | $662,718.00 | ★ $1,318,275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.86 |
| P/E Ratio | ★ N/A | $15.78 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $47.32 |
| 52 Week High | $5.79 | $87.32 |
| Indicator | MI | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 73.87 | 23.44 |
| Support Level | $3.80 | $55.95 |
| Resistance Level | $4.93 | $60.50 |
| Average True Range (ATR) | 0.38 | 2.35 |
| MACD | 0.17 | -0.58 |
| Stochastic Oscillator | 79.40 | 15.70 |
NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.